A Study on the Prevalence of HBsAg and Anti-HCV in Patients with Hepatocellular Carcinoma: Comparative Study with Healthy Blood Donors

Huh, Kwang; Lee, Jin Kyung; Choi, Soo Yong; Hong, Seok Il; Lee, Dong Soon

Abstract

BACKGROUND: The aim of this study was to evaluate the positive rates of hepatitis B surface antigen (HBsAg) and antibody to hepatitis C virus (anti-HCV) in patients with hepatocellular carcinoma (HCC), and to estimate the risk of developing HCC in association with HBsAg or anti- HCV positivity.
METHODS
HBsAg and anti-HCV (anti-c22-3 and anti-c200) were tested by enzyme immunoassay in 892 patients with HCC from 1991 to 1994. Data regarding the prevalence of these hepatitis markers in 4,269 healthy blood donors were obtained from the Central Blood Center of the Korea Red Cross and used for case-control study.
RESULTS
The positive rate of HBsAg was 72.3% (645/892) in patients with HCC and 2.7% (117/ 4,269) in blood donors, while that of anti-HCV was 7.6% (68/892) in patients with HCC and 0.3% (11/4,269) in blood donors. Six hundreds and thirty-six among 892 patients with HCC (71.3%) were only positive for HBsAg, 59 (6.6%) were only anti-HCV positive, and 9 (1.0%) were positive for both HBsAg and anti-HCV. The odds ratio (with 95% confidence interval: CI) comparing patients with HCC to healthy blood donors were 17.8 (CI: 4.7-61.5) for HBsAg positive, 11.9 (CI: 2.8-52.2) for anti-HCV positive, and 208.9 (CI: 18.6-2,345.7) for both HBsAg and anti-HCV positive. The risk estimates for both HBsAg and anti-HCV positve were not different from those for HBsAg positive or anti-HCV positive because the confidence interval of patients with both HBsAg and anti-HCV positive overlapped that of patients with HBsAg positive, or that of patients with anti-HCV positive.
CONCLUSIONS
Our results suggested that HBsAg was more important risk factor of HCC than anti-HCV and there was no interaction between HBsAg and anti-HCV in the development of HCC.